| Literature DB >> 30519488 |
Sylvester Yao Lokpo1, James Osei-Yeboah1, William K B A Owiredu2,3, Francis Abeku Ussher4, Verner Ndudiri Orish5, Felix Gadzeto6, Paul Ntiamoah6, Felix Botchway7, Ivan Muanah8, Romeo Asumbasiya Aduko1.
Abstract
BACKGROUND: This study aimed at evaluating the burden of renal dysfunction among people living with hypertension in the Asutifi-South District of the Brong Ahafo Region, who were attending clinic at the St. Elizabeth Hospital in Hwidiem.Entities:
Year: 2018 PMID: 30519488 PMCID: PMC6241342 DOI: 10.1155/2018/8428063
Source DB: PubMed Journal: Int J Hypertens Impact factor: 2.420
|
|
|
|
|---|---|---|
| Female | ≤62 (≤0.7) |
|
| Female | >62 (>0.7) |
|
|
| ||
| Male | ≤80 (≤0.9) |
|
| Male | >80 (>0.9) |
|
|
|
|
|
|---|---|---|
| G1 | Normal or high | ≥90 |
| G2 | Mildly decreased | 60 to 89 |
| G3 | Mildly to moderately decreased | 30 to 59 |
| G4 | Severely decreased | 15 to 29 |
| G5 | Kidney failure | <15 |
Socio-demographic characteristic of the population under study stratified by disease status.
| Parameter | Total | Diabetic and Hypertensive all together | Hypertensive only |
|---|---|---|---|
| Total Respondents | 200 (100) | 67 (33.5) | 133 (66.5) |
| Age (years) | 61 ± 10 | 62 ± 9 | 61 ± 10 |
| Weight (kg) | 64.23 ± 13.2 | 63.10 ± 13.8 | 64.80 ± 13.8 |
|
| |||
| Male | 48 (24.0) | 12 (17.9) | 36 (27.1) |
| Female | 152 (76.0) | 55 (82.1) | 97 (72.9) |
|
| |||
| Single | 3 (1.5) | 1 (1.5) | 2 (1.5) |
| Married | 127 (63.5) | 36 (53.7) | 91 (68.4) |
| Divorced | 9 (4.5) | 5 (7.5) | 4 (3.0) |
| Widowed | 58 (29.0) | 24 (35.8) | 34 (25.6) |
| Separated | 3 (1.5) | 1 (1.5) | 2 (1.5) |
|
| |||
| None | 86 (43.0) | 33 (49.3) | 53 (39.8) |
| Basic | 70 (35.0) | 21 (31.3) | 49 (36.8) |
| Secondary | 21 (10.5) | 9 (13.4) | 12 (9.0) |
| Tertiary | 23 (11.5) | 4 (6.0) | 19 (14.3) |
|
| |||
| Unemployed | 36 (18.0) | 12 (17.9) | 24 (18.0) |
| Employed | 161 (80.5) | 54 (80.6) | 107 (80.5) |
| On Pension | 3 (1.5) | 1 (1.5) | 2 (1.5) |
Data is presented as mean ± standard deviation and frequency with percentage in parenthesis.
Renal dysfunction categorization among study population using KDIGO eGFR Criteria stratified by disease status.
| eGFR Category | Total | Diabetic and Hypertensive all together | Hypertensive only | p-value | ||
|---|---|---|---|---|---|---|
| CG | G 1 | (≥90) | 73 (36.50) | 22 (32.84) | 51 (38.35) | |
| G 2 | (60 to 89) | 77 (38.50) | 25 (37.31) | 52 (39.10) | ||
| G 3 | (30 to 59) | 45 (22.50) | 17 (25.37) | 28 (21.05) | ||
| G 4 | (15 to 29) | 5 (2.50) | 3 (4.48) | 2 (1.50) | ||
| G 5 | (<15) | 0 (0.00) | 0 (0.00) | 0 (0.00) | ||
|
|
|
|
|
| ||
|
| ||||||
| 4v-MDRD | G 1 | (≥90) | 137 (68.50) | 41 (61.19) | 96 (72.18) | |
| G 2 | (60 to 89) | 44 (22.00) | 15 (22.39) | 29 (21.80) | ||
| G3 | (30 to 59) | 16 (8.00) | 9 (13.43) | 7 (5.26) | ||
| G4 | (15 to 29) | 3 (1.50) | 2 (2.99) | 1 (0.75) | ||
| G5 | (<15) | 0 (0.00) | 0 (0.00) | 0 (0.00) | ||
|
|
|
|
|
| ||
|
| ||||||
| CKD-EPI | G1 | (≥90) | 130 (65.00) | 40 (59.70) | 90 (67.67) | |
| G2 | (60 to 89) | 49 (24.50) | 16 (23.88) | 33 (24.81) | ||
| G3 | (30 to 59) | 17 (8.50) | 8 (11.94) | 9 (6.77) | ||
| G4 | (15 to 29) | 4 (2.00) | 3 (4.48) | 1 (0.75) | ||
| G5 | (<15) | 0 (0.00) | 0 (0.00) | 0 (0.00) | ||
|
|
|
|
|
| ||
Data is presented as frequency and percentage in parenthesis. 4v-MDRD – four variable Modification of Diet in Renal Disease, CG – Cockcroft-Gault, CKD-EPI – Chronic Kidney Disease Epidemiology collaboration, eGFR – estimated Glomerular Filtration Rate, CKD – Chronic Kidney Disease, G1-Category one, G2-Category two, G3-Category three, G4-Category four, G5-Category five.
Renal dysfunction categorization among study population using KDIGO eGFR Criteria stratified by gender.
| eGFR Category | Male | Female | p-value | ||
|---|---|---|---|---|---|
| CG | G1 | (≥90) | 22 (45.83) | 51 (33.55) | |
| G2 | (60 to 89) | 20 (41.67) | 57 (37.50) | ||
| G3 | (30 to 59) | 6 (12.50) | 39 (25.66) | ||
| G4 | (15 to 29) | 0 (0.00) | 5 (3.29) | ||
| G5 | (<15) | 0 (0.00) | 0 (0.00) | ||
|
|
|
|
| ||
|
| |||||
| 4v-MDRD | G1 | (≥90) | 38 (79.17) | 99 (65.13) | |
| G2 | (60 to 89) | 9 (18.75) | 35 (23.03) | ||
| G3 | (30 to 59) | 1 (2.08) | 15 (9.87) | ||
| G4 | (15 to 29) | 0 (0.00) | 3 (1.97) | ||
| G5 | (<15) | 0 (0.00) | 0 (0.00) | ||
|
|
|
|
| ||
|
| |||||
| CKD-EPI | G1 | (≥90) | 37 (77.08) | 93 (61.8) | |
| G2 | (60 to 89) | 9 (18.75) | 40 (26.32) | ||
| G3 | (30 to 59) | 2 (4.17) | 15 (9.87) | ||
| G4 | (15 to 29) | 0 (0.00) | 4 (2.63) | ||
| G5 | (<15) | 0 (0.00) | 0 (0.00) | ||
|
|
|
|
| ||
Data is presented as frequency with percentage in parenthesis. 4v-MDRD: four-variable modification of diet in renal disease, CG: Cockcroft-Gault, CKD-EPI: chronic kidney disease epidemiology collaboration, eGFR: estimated Glomerular Filtration Rate, CKD: chronic kidney disease, G1: category one, G2: category two, G3: category three, G4: category four, and G5: category five.
Prevalence of renal dysfunction stratified by age and medication.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
| ||||||
| <50 | 2 (7.40) | 4th | 1 (3.70) | 4th | 1 (3.70) | 4th |
| 50-59 | 11 (22.00) | 2nd | 10 (20.00) | 1st | 10 (20.00) | 1st |
| 60-69 | 19 (21.35) | 3rd | 5 (5.62) | 3rd | 6 (6.74) | 3rd |
| ≥70 | 18 (56.25) | 1st | 3 (9.38) | 2nd | 4 (11.76) | 2nd |
|
| ||||||
| ACE Inhibitor | 27 (24.32) | 2nd | 10 (9.01) | 2rd | 11 (9.91) | 3rd |
| CC Blocker | 36 (20.34) | 4th | 14 (7.91) | 3rd | 18 (10.17) | 2nd |
| Diuretics | 6 (23.08) | 3rd | 4 (15.38) | 1st | 4 (15.38) | 1st |
| AR Blocker | 17 (25.00) | 1st | 6 (8.82) | 4th | 6 (8.82) | 4th |
|
| 1 (12.50) | 5th | 0 (0.00) | 5th | 0 (0.00) | 5th |
| One | 7 (29.17) | 3rd | 2 (8.33) | 3rd | 3 (12.50) | 2nd |
| Two | 24 (25.00) | 4th | 9 (9.38) | 2nd | 8 (6.56) | 4th |
| Three | 6 (31.58) | 2nd | 3 (15.79) | 1st | 8 (18.18) | 1st |
| Four | 1 (33.33) | 1st | 0 (0.0) | 4rh | 1 (10.00) | 3rd |
Data is presented as frequency with percentage in parenthesis. 4v-MDRD: four-variable modification of diet in renal disease, CG: Cockcroft-Gault, CKD-EPI: chronic kidney disease epidemiology collaboration. ACE inhibitor: angiotensin converting enzyme inhibitor, and CC blocker: calcium channel blocker.